Hikal (HIKAL) | Stock Overview & Key Data
Hikal Performance Comparison
Stock Range
Today's Range
Low: ₹252.00
High: ₹257.50
on October 3, 2025
52 Week Range
Low: ₹245.00
High: ₹464.75
on August 22, 2025
on December 2, 2024
All-Time High: ₹742.00 on August 16, 2021
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR31.9B
EPS
5.13
P/E Ratio (TTM)
49.45
Forward P/E
19.74
P/B Ratio
2.48
PEG Ratio
-0.09
Div. Yield
0.74%
ROE
7.19%
Beta
0.444
Debt to Equity
60.58
Financial Highlights
Profitability
Gross Margin
49.69%
Operating Margin
-3.76%
Profit Margin
3.45%
Returns and Earnings
Return on Assets (TTM)
3.59%
Return on Equity (TTM)
7.19%
EBITDA
INR3.0B
Net Income (TTM)
INR633.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR148.69
Quarterly Revenue Growth (YoY)
-6.50%
Quarterly Earnings Growth (YoY)
-8.05%
Dividend Information
Last 12-Month Dividend
₹2.00
Current Dividend Yield
0.74%
3-Year Average Dividend Yield
0.20%
3-Year Average Annual Dividend
₹1.40
3-Year Total Dividends
₹4.20
Ex-Dividend Date
September 2, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Hikal HIKAL | 31.87B Small-cap | -0.41% | -5.17% | -26.85% | -40.31% | -36.94% | -29.25% | -24.34% | 43.57% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | 2.80% | 3.33% | -2.89% | -7.84% | -13.69% | -14.60% | 70.78% | 218.03% |
| Divi's Laboratories DIVISLAB | 1.61T Large-cap | 3.10% | -4.83% | -14.69% | 1.79% | -3.41% | 8.12% | 57.02% | 83.89% |
| Suven Life Sciences SUVEN | 48.20B Small-cap | -0.17% | -3.10% | -15.83% | 58.82% | 63.15% | 46.77% | 186.97% | 307.88% |
| Sequent Scientific SEQUENT | 48.13B Small-cap | -8.42% | 9.29% | -3.35% | 37.17% | 0.89% | -10.14% | 69.59% | 19.72% |
| Aarti Drugs AARTIDRUGS | 44.55B Small-cap | 4.61% | 0.24% | 1.59% | 41.06% | 7.93% | -4.79% | -0.89% | -50.06% |
Ownership & Short Interest
Insider Ownership
69.08%
Institutional Ownership
6.67%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
536K
Average 90-Day Volume
521K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is HIKAL's 52-week high and low?
- In the last 52 weeks, Hikal reached a high of ₹464.75 (on December 2, 2024) and a low of ₹245.00 (on August 22, 2025).
- What is the market cap and P/E ratio for HIKAL?
- Curious about Hikal's size and valuation? Its market capitalization stands at 31.87B. When it comes to valuation, the P/E ratio (trailing twelve months) is 49.45, and the forward P/E (looking ahead) is 19.74.
- Does HIKAL pay dividends? If so, what's the yield?
- Yes, Hikal is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.74%, and the company has paid an average of ₹1.40 per share annually over the past 3 years.
- Who are Hikal's main competitors or similar companies to consider before investing?
When looking at Hikal, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -14.60% 70.78% Divi's Laboratories
DIVISLAB1.61T Healthcare Drug Manufacturers - Specialty & Generic 8.12% 57.02% Suven Life Sciences
SUVEN48.20B Healthcare Drug Manufacturers - Specialty & Generic 46.77% 186.97% Sequent Scientific
SEQUENT48.13B Healthcare Drug Manufacturers - Specialty & Generic -10.14% 69.59% Aarti Drugs
AARTIDRUGS44.55B Healthcare Drug Manufacturers - Specialty & Generic -4.79% -0.89% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Hikal Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Hikal's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 7.19%, the Debt to Equity ratio from the most recent quarter is 60.58, and its Gross Profit Margin stands at 49.69%.
- What is the recent revenue and earnings growth for HIKAL?
- Looking at Hikal's growth, its revenue over the trailing twelve months (TTM) was INR18B. Compared to the same quarter last year (YoY), quarterly revenue grew by -6.50%, and quarterly earnings saw a YoY growth of -8.05%.
- How much of HIKAL stock is held by insiders and institutions?
- Wondering who owns Hikal stock? Company insiders (like executives and directors) hold about 69.08% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 6.67%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.